Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

As Donald Trump rounds out his nominations for key positions in his incoming administration, we’re keeping an eye on how his health-related picks might impact the future of the psychedelics field, notably drug development and policy reform efforts.

Of course, many of Trump’s picks will presumably need to be confirmed, but we will leave coverage of that process to other reporters.

Here, we review some key nominees from the past week or so, including any mentions of psychedelics, of a handful of health-related nominees…

FDA Pick - Marty Makary

Perhaps the biggest recent nominee-related news was that Martin (‘Marty’) Makary has been tapped as the next FDA commissioner and is thus set to replace Robert Califf. Many mainstream scientists and researchers have let out a sigh of relief, seeing Makary as a more moderate appointee than RFK Jr...